

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CF PharmTech, Inc.
長風藥業股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2652)

VOLUNTARY ANNOUNCEMENT
ACCEPTANCE OF MARKETING AUTHORIZATION APPLICATION FOR
TIOTROPIUM BROMIDE INHALATION POWDER BY THE NMPA

This announcement is made by CF PharmTech, Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the latest research and development of the Group.

INTRODUCTION

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that the marketing authorization application (the “**Application**”) for the Company’s tiotropium bromide inhalation powder (the “**Product**”), has been accepted by the National Medical Products Administration of the People’s Republic of China (“**NMPA**”). The relevant information is hereby announced as follows:

Product name	:	Tiotropium bromide inhalation powder
Application type	:	Marketing authorization application
Acceptance number	:	CYHS2601031
Applicant	:	The Company
Proposed Indications	:	Treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), and the reduction of COPD exacerbations

STRATEGIC SIGNIFICANCE

Tiotropium bromide is a long-acting muscarinic antagonist (LAMA) that provides sustained bronchodilation over a 24-hour period by inhibiting the cholinergic (bronchoconstricting) effects of acetylcholine through binding to muscarinic receptors on bronchial smooth muscle. The Product is designed for delivery to the deep lung via a specific inhalation powder device. Tiotropium bromide inhalation powder is one of the most widely prescribed inhaled formulations globally for the treatment of COPD.

Leveraging its established oral and nasal inhalation drug delivery technology platform, the Company has to date built a comprehensive product portfolio covering multiple indications for respiratory and rhinitis conditions. The acceptance of the Application for the Product further completes the Company's range of inhalation products for COPD, expanding both product coverage and therapeutic depth, and reinforcing its specialized positioning in the broader inhaled respiratory formulations sector.

The Group will maintain active communication with the NMPA and advance subsequent review procedures in accordance with regulatory requirements.

RISK WARNING

The acceptance of the Application is an administrative step in the review process and does not constitute marketing approval. The Product remains subject to further review by the NMPA, and there is no assurance that the Application will be approved. Given the inherent risks and uncertainties in pharmaceutical research, development and commercialization, **shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.**

ABOUT THE COMPANY

As a global innovator in inhalation drug delivery technology, CF PharmTech, Inc. is dedicated to building multidisciplinary bridges between complex formulations and unmet clinical needs. The Company is not only a specialist in the development of complex inhalation formulations with high barriers to entry, but also a platform-based innovative pharmaceutical company with integrated capabilities spanning device engineering, precision drug delivery, global regulatory filing and commercialization.

Leveraging its fully self-developed, globally integrated end-to-end capabilities – from exhalation-powered nasal spray delivery systems and liposomal inhalation technology to siRNA nucleic acid delivery platforms – the Company is systematically advancing its proprietary innovative pipeline for the markets in China, the United States and Europe. Its therapeutic areas encompass respiratory diseases (including asthma, chronic obstructive pulmonary disease and bronchiectasis) and nasal diseases (including allergic rhinitis and chronic rhinosinusitis), with strategic expansion into pulmonary fibrosis, pulmonary arterial hypertension, rare pulmonary infections and central nervous system disorders, as the Company advances precision drug delivery via the nose-to-brain pathway.

The Company has established an extensive multi-dimensional commercialization network in China and, through its globally compliant manufacturing systems and deepening international presence, is steadily advancing towards its goal of becoming a global innovative pharmaceutical enterprise.

By order of the Board

CF PharmTech, Inc.

長風藥業股份有限公司

Dr. LIANG Bill Wenqing

Chairperson, Executive Director and Chief Executive Officer

Hong Kong, May 26, 2026

As at the date of this announcement, the Board comprises Dr. LIANG Bill Wenqing, Dr. LI LI BOVET, Dr. LI Qi and Ms. ZHU Yuyu as executive Directors, Mr. CHEN Penghui, Mr. CAI Lei and Dr. YI Hua as non-executive Directors, and Dr. JIN Jian, Ms. WANG Lijuan, Mr. WEI Shirong and Mr. IP Wang Hoi as independent non-executive Directors.